Transgenic Group Past Earnings Performance
Past criteria checks 0/6
Transgenic Group's earnings have been declining at an average annual rate of -9.4%, while the Biotechs industry saw earnings growing at 11.1% annually. Revenues have been growing at an average rate of 4.3% per year.
Key information
-9.4%
Earnings growth rate
-9.4%
EPS growth rate
| Biotechs Industry Growth | 31.9% |
| Revenue growth rate | 4.3% |
| Return on equity | -3.9% |
| Net Margin | -1.7% |
| Last Earnings Update | 30 Sep 2024 |
Revenue & Expenses Breakdown
How Transgenic Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 13,017 | -226 | 2,291 | 0 |
| 30 Jun 24 | 12,685 | -173 | 2,217 | 0 |
| 31 Mar 24 | 13,083 | 4 | 2,146 | 0 |
| 31 Dec 23 | 12,708 | -629 | 2,146 | 0 |
| 30 Sep 23 | 12,264 | -415 | 2,119 | 0 |
| 30 Jun 23 | 12,239 | -306 | 2,080 | 0 |
| 31 Mar 23 | 11,429 | -409 | 2,019 | 0 |
| 31 Dec 22 | 11,395 | 1,256 | 1,988 | 0 |
| 30 Sep 22 | 11,416 | 949 | 2,013 | 0 |
| 30 Jun 22 | 11,733 | 1,243 | 1,992 | 0 |
| 31 Mar 22 | 12,576 | 1,876 | 1,998 | 0 |
| 31 Dec 21 | 12,833 | 900 | 2,051 | 0 |
| 30 Sep 21 | 13,068 | 1,502 | 1,961 | 0 |
| 30 Jun 21 | 12,152 | 1,164 | 1,929 | 0 |
| 31 Mar 21 | 11,046 | 546 | 1,881 | 0 |
| 31 Dec 20 | 11,012 | 31 | 1,764 | 0 |
| 30 Sep 20 | 10,535 | -374 | 1,710 | 0 |
| 30 Jun 20 | 10,902 | -365 | 1,643 | 0 |
| 31 Mar 20 | 11,046 | -440 | 1,605 | 0 |
| 31 Dec 19 | 10,144 | 174 | 1,446 | 0 |
| 30 Sep 19 | 9,541 | 133 | 1,372 | 0 |
| 30 Jun 19 | 8,932 | 133 | 1,312 | 0 |
| 31 Mar 19 | 8,674 | 202 | 1,228 | 0 |
| 31 Dec 18 | 8,607 | 97 | 1,231 | 0 |
| 30 Sep 18 | 7,070 | 121 | 1,085 | 0 |
| 30 Jun 18 | 5,355 | 53 | 918 | 0 |
| 31 Mar 18 | 3,601 | 20 | 759 | 0 |
| 31 Dec 17 | 2,178 | 16 | 619 | 0 |
| 30 Sep 17 | 2,172 | 29 | 593 | 0 |
| 30 Jun 17 | 2,247 | 68 | 586 | 0 |
| 31 Mar 17 | 2,302 | 80 | 594 | 0 |
| 31 Dec 16 | 2,488 | 127 | 597 | 0 |
| 30 Sep 16 | 2,524 | 96 | 608 | 0 |
| 30 Jun 16 | 2,378 | 50 | 620 | 0 |
| 31 Mar 16 | 2,290 | 14 | 622 | 0 |
| 31 Dec 15 | 2,141 | 25 | 586 | 40 |
| 30 Sep 15 | 1,992 | 43 | 597 | 40 |
| 30 Jun 15 | 1,986 | 44 | 594 | 40 |
| 31 Mar 15 | 1,958 | 17 | 593 | 40 |
| 31 Dec 14 | 1,801 | -70 | 589 | 42 |
| 30 Sep 14 | 1,773 | -64 | 599 | 42 |
| 30 Jun 14 | 1,709 | -71 | 595 | 42 |
| 31 Mar 14 | 1,617 | -113 | 552 | 42 |
| 31 Dec 13 | 1,274 | -6 | 480 | 31 |
Quality Earnings: 2342 is currently unprofitable.
Growing Profit Margin: 2342 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2342 is unprofitable, and losses have increased over the past 5 years at a rate of 9.4% per year.
Accelerating Growth: Unable to compare 2342's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2342 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4%).
Return on Equity
High ROE: 2342 has a negative Return on Equity (-3.86%), as it is currently unprofitable.